Clinical Trial Results:
A randomised, double-blind, parallel groups, placebo-controlled, multi-centre trial in oocyte donors assessing the effects of barusiban, a selective oxytocin antagonist, on uterine contractions on the day of embryo transfer
Due to the EudraCT – Results system being out of service between 31 July 2015 and 12 January 2016, these results have been published in compliance with revised timelines
Summary
|
|
EudraCT number |
2009-012323-29 |
Trial protocol |
CZ ES BE |
Global end of trial date |
02 Dec 2010
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
06 Jan 2017
|
First version publication date |
06 Jan 2017
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
FE 200440 CS11
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT01043120 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Ferring Pharmaceuticals A/S
|
||
Sponsor organisation address |
Kay Fiskers Plads 11, Copenhagen S, Denmark, 2300
|
||
Public contact |
Clinical Development Support, Ferring Pharmaceuticals, DK0-Disclosure@ferring.com
|
||
Scientific contact |
Clinical Development Support, Ferring Pharmaceuticals, DK0-Disclosure@ferring.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
02 Dec 2010
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
30 May 2010
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
02 Dec 2010
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
To evaluate the effects of barusiban compared to placebo on uterine contractions on the day of embryo transfer.
|
||
Protection of trial subjects |
The trial was performed in accordance with the Declaration of Helsinki and its amendments in force at the initiation of the trial.
|
||
Background therapy |
An ultrasound contrast agent (SONOVUE) was used as non-investigational product (NIMP) during this trial. SONOVUE was administered intrauterinely via an embryo transfer catheter during the mock embryo transfer procedure. | ||
Evidence for comparator |
This was a randomised controlled trial with placebo as the comparator to adequately document the efficacy and safety of barusiban. A placebo group was justified for this trial as there is no therapy available for this indication. | ||
Actual start date of recruitment |
02 Feb 2010
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Belgium: 23
|
||
Country: Number of subjects enrolled |
Spain: 14
|
||
Country: Number of subjects enrolled |
Czech Republic: 62
|
||
Worldwide total number of subjects |
99
|
||
EEA total number of subjects |
99
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
99
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
||||||||||||||||
Recruitment
|
||||||||||||||||
Recruitment details |
A total of 4 sites randomised subjects into the trial : 1 in Belgium, 2 in Czech Republic, and 1 in Spain. | |||||||||||||||
Pre-assignment
|
||||||||||||||||
Screening details |
A total of 102 subjects were screened in the trial, of whom 99 subjects were randomised: 49 to barusiban, and 50 to placebo. | |||||||||||||||
Period 1
|
||||||||||||||||
Period 1 title |
Overall Period
|
|||||||||||||||
Is this the baseline period? |
Yes | |||||||||||||||
Allocation method |
Randomised - controlled
|
|||||||||||||||
Blinding used |
Double blind | |||||||||||||||
Roles blinded |
Subject, Investigator, Data analyst, Assessor | |||||||||||||||
Arms
|
||||||||||||||||
Are arms mutually exclusive |
Yes
|
|||||||||||||||
Arm title
|
Barusiban | |||||||||||||||
Arm description |
Subjects randomised to barusiban investigational medicinal product (IMP) were included in this group. | |||||||||||||||
Arm type |
Experimental | |||||||||||||||
Investigational medicinal product name |
Barusiban
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
||||||||||||||||
Pharmaceutical forms |
Solution for injection
|
|||||||||||||||
Routes of administration |
Intravenous use
|
|||||||||||||||
Dosage and administration details |
Subjects received barusiban (intravenous [IV] bolus 20 mg for 1 minute followed by an IV infusion of 19 mg for up to 59 minutes). The maximum total duration of administration was 60 minutes.
|
|||||||||||||||
Arm title
|
Placebo | |||||||||||||||
Arm description |
Subjects randomised to placebo IMP were included in this group. | |||||||||||||||
Arm type |
Placebo | |||||||||||||||
Investigational medicinal product name |
Placebo
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
||||||||||||||||
Pharmaceutical forms |
Solution for injection
|
|||||||||||||||
Routes of administration |
Intravenous use
|
|||||||||||||||
Dosage and administration details |
Subjects received IV bolus of saline (sodium chloride 0.9%) for 1 minute followed by an IV infusion of saline for up to 59 minutes.
|
|||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Barusiban
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects randomised to barusiban investigational medicinal product (IMP) were included in this group. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Placebo
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects randomised to placebo IMP were included in this group. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis sets
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set title |
Intention-to-treat (ITT)
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set type |
Intention-to-treat | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set description |
All randomised and exposed subjects were included in this analysis set.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set title |
Per protocol (PP) analysis set
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set type |
Per protocol | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set description |
All the subjects in the ITT analysis set except those who met any of the criteria considered as major protocol deviations were included in this analysis set.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set title |
Safety analysis set
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set type |
Safety analysis | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set description |
All randomised and exposed subjects were included in this analysis set.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Barusiban
|
||
Reporting group description |
Subjects randomised to barusiban investigational medicinal product (IMP) were included in this group. | ||
Reporting group title |
Placebo
|
||
Reporting group description |
Subjects randomised to placebo IMP were included in this group. | ||
Subject analysis set title |
Intention-to-treat (ITT)
|
||
Subject analysis set type |
Intention-to-treat | ||
Subject analysis set description |
All randomised and exposed subjects were included in this analysis set.
|
||
Subject analysis set title |
Per protocol (PP) analysis set
|
||
Subject analysis set type |
Per protocol | ||
Subject analysis set description |
All the subjects in the ITT analysis set except those who met any of the criteria considered as major protocol deviations were included in this analysis set.
|
||
Subject analysis set title |
Safety analysis set
|
||
Subject analysis set type |
Safety analysis | ||
Subject analysis set description |
All randomised and exposed subjects were included in this analysis set.
|
|
|||||||||||||
End point title |
Absolute change from Baseline in frequency of uterine contractions at 30 minutes after start of dosing | ||||||||||||
End point description |
Data are presented for the ITT analysis set.
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
From Baseline to 30 minutes after start of dosing.
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Frequency at 30 minutes - barusiban vs placebo | ||||||||||||
Statistical analysis description |
Analysis of change in contraction frequency from Baseline at 30 minutes was done using analysis of covariance (ANCOVA) on the ITT analysis set.
|
||||||||||||
Comparison groups |
Barusiban v Placebo
|
||||||||||||
Number of subjects included in analysis |
78
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.014 | ||||||||||||
Method |
t-test, 2-sided | ||||||||||||
Parameter type |
Mean difference (final values) | ||||||||||||
Point estimate |
-0.58
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
-1.04 | ||||||||||||
upper limit |
-0.12 |
|
||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
Overall Treatment Period
|
|||||||||||||||||||||||||||||||||||||||||||||
Adverse event reporting additional description |
Treatment-emergent adverse events (TEAEs) were presented and evaluated by treatment groups. Data were presented for safety analysis set.
|
|||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | |||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | |||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
12.1
|
|||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Barusiban
|
|||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects randomised to barusiban IMP were included in this group. | |||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Placebo
|
|||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects randomised to placebo IMP were included in this group. | |||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 0% | ||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |